Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
National supply-chain survey of drug manufacturer back orders
Autore:
Wellman, GS;
Indirizzi:
Ferris State Univ, Coll Pharm, Big Rapids, MI 49307 USA Ferris State UnivBig Rapids MI USA 49307 Pharm, Big Rapids, MI 49307 USA
Titolo Testata:
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
fascicolo: 13, volume: 58, anno: 2001,
pagine: 1224 - 1228
SICI:
1079-2082(20010701)58:13<1224:NSSODM>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Keywords:
administration; anti-infective agents; benzodiazepine antagonists; blood derivatives; cardiac drugs; communication; data collection; drug distribution; hypotensive agents; industry, pharmaceutical; inventory; manufacturers; pharmacy, institutional; raw materials; steroids, cortico-; thrombolytic agents; wholesalers;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
6
Recensione:
Indirizzi per estratti:
Indirizzo: Wellman, GS Ferris State Univ, Coll Pharm, 220 Ferris Dr, Big Rapids, MI 49307 USA Ferris State Univ 220 Ferris Dr Big Rapids MI USA 49307 07 USA
Citazione:
G.S. Wellman, "National supply-chain survey of drug manufacturer back orders", AM J HEAL S, 58(13), 2001, pp. 1224-1228

Abstract

The impact of manufacturer back orders on the supply chain for pharmaceuticals in the institutional setting was studied. A questionnaire was distributed during May and June 2000 to 600 institutional pharmacies affiliated with a major national drug and supply group purchasing organization. The instrument included questions on basic institutional demographics, perceptions about the frequency of manufacturer back ordersfor pharmaceuticals, the qualify of communication with manufacturers and wholesalers about back orders, the two most significant back orders that hadoccurred in the 12 months preceding the survey, and the reasons for and impact of back orders. A total of 170 usable surveys were returned (net response rate, 28.3%). Reported manufacturer back orders included an array of drug classes, including blood products, antimicrobials, antiarrhythmics, benzodiazepine antagonists, thrombolytics, corticosteroids, and antihypertensives, Respondents perceived significant back orders as increasing in frequency. Communi-cation bymanufacturers and wholesalers about back orders was reported to be relatively poor. A raw-material shortage was the most common reason given by manufacturers for back orders (36.5%), Followed by a regulatory issue (23.2%). In most cases (92%), medical staff members had to be contacted, indicating an interruption in the normal drug distribution process. In over a third of instances, respondents stated that the back order resulted in less optimal therapy. A survey found that manufacturer back orders for pharmaceuticals were increasing in frequency and that information flow within the supply chain was insufficient to meet the needs of end users.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 13:28:03